Cargando…

Neoadjuvant therapy for resectable pancreatic cancers

Detalles Bibliográficos
Autores principales:	Inoue, Yosuke, Ito, Hiromichi, Takahashi, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396094/ https://www.ncbi.nlm.nih.gov/pubmed/36016746 http://dx.doi.org/10.21037/hbsn-22-31

Ejemplares similares

Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy—Arterial Resection, Arterial Divestment and Total Pancreatectomy
por: Inoue, Yosuke, et al.
Publicado: (2021)

Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
por: Kim, Dong Uk
Publicado: (2022)

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases
por: Ichida, Hirofumi, et al.
Publicado: (2019)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer?
por: Robertson, Francis P., et al.
Publicado: (2023)

Preoperative Decision to Perform Portal Vein Resection Improves Survival in Patients With Resectable Pancreatic Head Cancer Adjacent to Portal Vein
por: Terasawa, Muga, et al.
Publicado: (2021)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
por: Chawla, Akhil, et al.
Publicado: (2019)

Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
por: Kim, Dong Uk
Publicado: (2023)

Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer
por: Smaglo, Brandon G.
Publicado: (2023)

Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?)
por: Søreide, Kjetil
Publicado: (2021)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
por: Lambert, Aurélien, et al.
Publicado: (2021)

Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer
por: Ashida, Reiko, et al.
Publicado: (2020)

Diabetogenic liver metastasis from pancreatic cancer: a case report
por: Kiritani, Sho, et al.
Publicado: (2022)

Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
por: Taboada, Alvaro Gregorio Morales, et al.
Publicado: (2021)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
por: Hussien, Nervana, et al.
Publicado: (2022)

Neoadjuvant therapy for pancreatic cancer
por: Gugenheim, Jean, et al.
Publicado: (2021)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis
por: Zhang, Hao-Qi, et al.
Publicado: (2022)

HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma
por: Nakamura, Toru, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer
por: Okabayashi, Takehiro, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials
por: Liu, Shangtong, et al.
Publicado: (2023)

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy
por: Chao, Ying-Jui, et al.
Publicado: (2014)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Sinistral Portal Hypertension after Pancreaticoduodenectomy with Splenic Vein Resection: Pathogenesis and Its Prevention
por: Ono, Yoshihiro, et al.
Publicado: (2021)

A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy
por: Hwang, Ho Kyoung, et al.
Publicado: (2020)

Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
por: Oshima, Minoru, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
por: Limbu, Yugal, et al.
Publicado: (2021)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ge5j4dos8judn681son681kqrq